It has long been hypothesized that dysregulation of central norepinephrine (NE) neuronal systems might be involved in the expression if not the development of major affective disorders, including depression and mania (Schatzberg and Schildkraut 1995; Schildkraut 1965) . The noradrenergic neurons of the locus coeruleus (LC), situated in the dorsal pons, project widely throughout the central nervous system, representing the source of noradrenergic terminals innervating many forebrain and limbic regions such as the amygdala, hippocampus, hypothalamus and neocortex (Moore and Bloom 1979). As such, these neurons are ideally poised to exert global modulatory or state-related changes in brain activity. Central NE, and the LC in particular, is hypothesized to play an important role in attention, arousal and behavioral activation (Aston-Jones et al. 1991; Charney et al. 1990; Foote et al. 1983; Puumala et al. 1997; Siegel and Rogawski 1988) , all of which may be severely disrupted in mood disorders, especially those involving a manic component such as bipolar affective disorder. Thus, the noradrenergic neurons of the LC may represent potential targets for mood stabilizing drug treat- Effective therapeutic agents have been developed for the treatment of bipolar disorder. Lithium has been the primary treatment for bipolar disorder, although its side effects are many and often severe, and its mechanism of action is still relatively unknown (Bowden et al. 1994) . Recently, certain classes of antiepileptic agents, including valproic acid (VPA), have proven to be as effective as lithium in the treatment of mania and bipolar disorder, and possess a more benign adverse effect profile and a broader therapeutic margin of safety (Bowden et al. 1994; Loscher 1993) . The mechanism of action of VPA for the treatment of affective disorders is largely unknown. By contrast, the mechanisms by which it acts as an antiepileptic have been more extensively examined. The biochemical effects of VPA occur rapidly, and include the inhibition of GABA transaminase (and thus inhibition of GABA catabolism) and a decrease in sodium channel activity (Van den Berg et al. 1993) . Similarly, the antiepileptic effects of VPA are observed quickly, whereas the antimanic effects of VPA require a much longer course of treatment, as long as 2-3 weeks (Bowden et al. 1994 ). Because of this, the mechanisms of action underlying the antimanic action of VPA may be distinct from those underlying its antiepileptic effects. Thus, it would be informative to investigate the induction of long-term regulatory, reactive, or compensatory alterations that may occur in the brain after administration of mood stabilizing drugs such as VPA.
It has long been hypothesized that dysregulation of central norepinephrine (NE) neuronal systems might be involved in the expression if not the development of major affective disorders, including depression and mania (Schatzberg and Schildkraut 1995; Schildkraut 1965) . The noradrenergic neurons of the locus coeruleus (LC), situated in the dorsal pons, project widely throughout the central nervous system, representing the source of noradrenergic terminals innervating many forebrain and limbic regions such as the amygdala, hippocampus, hypothalamus and neocortex (Moore and Bloom 1979) . As such, these neurons are ideally poised to exert global modulatory or state-related changes in brain activity. Central NE, and the LC in particular, is hypothesized to play an important role in attention, arousal and behavioral activation (Aston-Jones et al. 1991; Charney et al. 1990; Foote et al. 1983; Puumala et al. 1997; Siegel and Rogawski 1988) , all of which may be severely disrupted in mood disorders, especially those involving a manic component such as bipolar affective disorder. Thus, the noradrenergic neurons of the LC may represent potential targets for mood stabilizing drug treat-N EUROPSYCHOPHARMACOLOGY 2000 -VOL . 22 , NO . 1 ment, and are likely to reflect at least some of the regulatory mechanisms responsible for their therapeutic effects.
Effective therapeutic agents have been developed for the treatment of bipolar disorder. Lithium has been the primary treatment for bipolar disorder, although its side effects are many and often severe, and its mechanism of action is still relatively unknown (Bowden et al. 1994) . Recently, certain classes of antiepileptic agents, including valproic acid (VPA), have proven to be as effective as lithium in the treatment of mania and bipolar disorder, and possess a more benign adverse effect profile and a broader therapeutic margin of safety (Bowden et al. 1994; Loscher 1993) . The mechanism of action of VPA for the treatment of affective disorders is largely unknown. By contrast, the mechanisms by which it acts as an antiepileptic have been more extensively examined. The biochemical effects of VPA occur rapidly, and include the inhibition of GABA transaminase (and thus inhibition of GABA catabolism) and a decrease in sodium channel activity (Van den Berg et al. 1993) . Similarly, the antiepileptic effects of VPA are observed quickly, whereas the antimanic effects of VPA require a much longer course of treatment, as long as 2-3 weeks (Bowden et al. 1994) . Because of this, the mechanisms of action underlying the antimanic action of VPA may be distinct from those underlying its antiepileptic effects. Thus, it would be informative to investigate the induction of long-term regulatory, reactive, or compensatory alterations that may occur in the brain after administration of mood stabilizing drugs such as VPA.
The long time course over which adaptations occur with mood stabilizers suggests that changes in gene expression for components of brain neurotransmitter systems important in regulation of affect may be involved. Past results suggest that drugs used in the treatment of affective disorders can indeed induce regulatory or compensatory alterations in gene expression for various components of the noradrenergic neurotransmitter system. For example, administration of tricyclic antidepressants such as desipramine decreases tyrosine hydroxylase (TH) mRNA expression in the LC (Brady et al. 1991; Morilak et al. 1998; Nestler et al. 1990 ). Thus, in the first experiment of the present study, we examined potential changes in TH gene expression in the LC following acute and chronic administration of VPA. To test for the specificity of any VPA-induced changes in TH mRNA expression, we also measured mRNA encoding two other components of the noradrenergic system expressed in the LC, the norepinephrine transporter (NET) and ␣ 2A adrenergic autoreceptor. In the second experiment, the effects of acute or chronic VPA treatment on acute stress-reactivity of TH gene expression in the LC noradrenergic neurons were examined. In addition, because of the presumed role of NE in activation of the hypothalamic-pituitary-adrenal stress axis, changes in plasma ACTH levels following acute stress in VPA-treated rats were also measured. Portions of this work have been presented in abstract form (Morilak et al. 1998) .
MATERIALS AND METHODS

Experiment 1: Effect of Valproate on Basal LC Gene Expression
70 adult male Sprague-Dawley rats (250-300 g; Harlan, Indianapolis, IN) were group housed, 3 per cage, for a minimum of 10 days prior to initiating the experiment. This experiment was conducted in three replications (the animals tested in the third replicate also served as unstressed control subjects in Experiment 2 below). Animals were maintained on a 12:12 light/dark cycle (lights on at 0700 h), and allowed ad libitum access to food and water throughout. The animals were randomly assigned to one of four treatment groups. The drug treatments were vehicle (sterile distilled water) or VPA (600 mg/kg/day) administered either acutely (2 days) or chronically (2 weeks). In pilot studies, it was found that the VPA solution gelled at the concentrations necessary to deliver the desired daily dose by osmotic minipump. Thus, because of the short half-life of VPA in rats (approximately 90 min), VPA was administered s.c. 3X daily (200 mg/kg in each injection in a concentration of 200 mg/ml sterile distilled water) at 0700 h, 1500 h and 2300 h (Loscher et al. 1989) . In a series of preliminary investigations, it was determined that this dosing regimen consistently produced plasma VPA levels, sampled 4 hr after the last injection, of 40-50 g/ml, very close to the target therapeutic level of 50 g/ml. Control animals received equivalent volumes of vehicle on the same injection schedule. Four hours after the final injection, animals were sacrificed by rapid decapitation, the brains were removed, frozen by immersion in isopentane on dry ice, and stored at Ϫ 70 Њ C until use (less than one month).
Experiment 2: Effect of Restraint Stress on LC Gene Expression and Plasma ACTH Levels After Valproate Treatment
68 adult male Sprague-Dawley rats (33 of which were also used in Experiment 1) were housed and maintained as above. Drug treatment regimens were also identical to those described above. Beginning two to three hours after the final injection, half of the control and valproate-treated rats were subjected to 1 hr restraint stress using Centrap restraint devices (Fisher Scientific) . At the end of the 1 hr restraint period, rats were then decapitated, trunk blood was collected in chilled polypropylene tubes containing EDTA (1mg/1ml blood collected), and the brains were processed as above.
In Situ Hybridization
Procedures for in situ hybridization were essentially the same for both experiments. Six sequential series of 20-m adjacent sections were cut through the LC on a cryostat. Sections were thaw mounted onto silanecoated glass microscope slides, two per slide. The slidemounted sections were fixed 15 min in 4% paraformaldehyde, dehydrated in 70% ethanol, air-dried and stored at Ϫ 70 Њ C until a sufficient number of brains had been cut for simultaneous processing (typically 12-16 brains per hybridization). Within each hybridization procedure, an equal number of brains from each treatment group at any time point were cut, processed and quantified together to minimize systematic variability.
Radiolabeled riboprobes were synthesized from linearized cDNA plasmids using a commercially available transcription kit (Stratagene) according to the manufacturer's directions, with the addition of ␣ -35 S-UTP (New England Nuclear) to a specific activity of 2 ϫ 10 9 cpm/ g. The 275 nt TH probe was transcribed from a cDNA template obtained from Dr. Stanley Watson, University of Michigan; the 690 nt ␣ 2A probe was synthesized from a cDNA template obtained from Dr. Stephen Lanier, Harvard Medical School, and the 660 nt NET riboprobe was transcribed from a cDNA template obtained from Dr. Richard Simerly, Oregon Health Sciences University. After transcription, riboprobes were separated from free nucleotide using Sephadex spin columns.
All solutions used for prehybridization and hybridization were treated with diethyl pyrocarbonate and autoclaved or filter sterilized. At the time of hybridization, brain sections were thawed, hydrated in PBS, acetylated in 0.25% acetic anhydride/0.1 M triethanolamine, pH 8.0, and rinsed in 2X SSC (1X SSC is 150 mM sodium chloride, 15 mM sodium citrate, pH 7.2). Sections were then dehydrated in an ascending series of ethanol washes, delipidated in chloroform, and airdried before hybridization. Hybridization buffer consisted of 50 mM sodium phosphate, 3X SSC, 5X Denhardt's solution, 0.1 mg/ml salmon sperm DNA, 0.1 mg/ml yeast tRNA, 10 mM dithiothreitol, 10% dextran sulfate, and 50% deionized formamide. Sections were hybridized under glass coverslips in 60 l of hybridization buffer to which radiolabeled riboprobe had been added to a final concentration of 4 ϫ 10 7 cpm/ml (approximately 20 ng/ml). They were then placed on racks and incubated overnight in a sealed humidified chamber at 60 Њ C. Control probes synthesized from the sense strand of each template were applied to a small number of sections to verify specificity of the label.
All post-hybridization solutions contained 10 mM ␤ -mercaptoethanol. After hybridization, excess probe was removed by rinsing in four washes of 2X SSC, then digesting the sections with RNase A (20 g/ml, 30 minutes at 37 Њ C). They were then taken through a series of rinses of increasing stringency: 10 min each in 1X, 0.5X, and 0.2X SSC. The conditions for the final high-stringency wash varied depending on the probes: for the TH and the ␣ 2A probes, sections were washed for 3 x 1 hr in 0.1X SSC, 15% formamide at 60 Њ C. For the NET probe, sections were washed for 3 ϫ 1 hr in 0.2X SSC at 60 Њ C. Following the high-stringency wash, sections were rinsed in 1X SSC, dehydrated and apposed, along with 14 C-radioactive standards, to Kodak Biomax MR X-ray film for 19 hr (TH), 76 hr ( ␣ 2A ) or 19 hr (NET).
Data Analysis
Digitized images of film autoradiograms were captured with a Sony XC-77 CCD camera coupled to a Scion LG-3 capture board in a PowerMac 7100 computer. Image signal intensity on each film was calibrated using a standard curve constructed from 14 C-standards exposed along with the sections. Signal overlying the LC was then analyzed densitometrically using the public domain NIH-Image software package (v. 1.55, Wayne Rasband, NIH). Integrated density for each probe, expressed in standard units of nCi/mg, was measured in 4-6 LC sections per brain, corresponding to plates 56-58 in the Atlas of Paxinos and Watson (Paxinos and Watson 1986 ). Mean integrated density was then calculated from these measurements to generate a single value for each animal. The resulting data were then analyzed by ANOVA, followed by post-hoc analyses, where appropriate, with the Newman-Keuls test. Significance of any observed differences was determined at p Ͻ .05.
Plasma ACTH Measures
Upon collection of the trunk blood, samples were centrifuged at 4500 rpm for 15 min, at which time plasma was removed, frozen, and stored at Ϫ 80 Њ C until assayed. Plasma ACTH values were determined in duplicate 200 l samples by direct radioimmunoassay according to manufacturer's instructions (Nichols Institute Diagnostics, San Juan Capistrano, CA). Resulting data were analyzed by ANOVA, followed by post-hoc analyses with Newman-Keuls test. Significance of any observed differences was determined at p Ͻ .05.
RESULTS
Hybridization with all three riboprobes produced a specific and robust signal overlying noradrenergic neu-rons of the LC ( Figures 1A, 2A, 3A) . In no case was any signal ever observed with the sense control probes. Treatment with VPA exerted a significant effect on body weight gain during the course of the treatment. Vehicle-treated animals gained 55 Ϯ 3 g during the 2-week treatment period, while VPA-treated rats gained 26 Ϯ 2 g ( n ϭ 20 each, t ϭ 81.66, p Ͻ .0001). Even acute VPA treatment attenuated the mean increase in body weight seen during the two-day drug treatment period (10 Ϯ 4 g vs. 0 Ϯ 4 g, n ϭ 14 each, t ϭ 41.26, p Ͻ .0001).
Experiment 1: Effect of Valproate on Basal LC Gene Expression
Treatment of rats with VPA caused a significant increase in TH message expression in the LC (F 1,66 ϭ 20.268, p Ͻ .001; Figure 1 ). Post-hoc comparisons further revealed that, as compared to the respective vehicle-treated control animals, TH mRNA expression was significantly elevated in both acute and chronic valproate-treated rats, to 116% and 126% of their vehicletreated controls, respectively (Figure 1 ). By contrast, neither acute nor chronic VPA treatment induced significant changes in NET (Figure 2 VPA treatment in Experiment 2 (n ϭ 5-7 per group, Figure 4A ). Acute restraint-stress induced a significant increase in TH mRNA expression in vehicle-treated rats, to 128% of unstressed controls (p Ͻ .05). By contrast, restraint stress induced a modest nonsignificant increase in TH mRNA expression in acute VPA-treated animals, to 113% of unstressed VPA-treated rats ( Figure 4A ).
The increase in TH mRNA expression seen following chronic VPA-treatment in Experiment 1 was also replicated in Experiment 2. There was again a significant elevation in basal TH mRNA expression following chronic VPA treatment to 120% of vehicle-treated control levels (n ϭ 9-11 per group, p Ͻ .05, Figure 4B ). Chronic VPA treatment also had a significant attenuating effect on the acute restraint stress-induced elevation in TH mRNA expression in the LC. Whereas restraint stress induced a significant elevation in TH mRNA in vehicle-treated animals to 126% of unstressed controls, there was no change in TH mRNA expression in the LC following restraint stress in the chronic VPA-treated rats ( Figure 4B ).
In the acutely treated animals, there was, as expected, a significant effect of stress on plasma ACTH levels (F 1,23 ϭ 80.24; p Ͻ .0001). Post-hoc analyses revealed that the increase in plasma ACTH seen in acute VPA-treated rats was less than that seen in the vehicletreated control group (p Ͻ .05, Figure 5A ). Similarly, stress induced a significant increase in plasma ACTH in chronically-treated animals (F 1,28 ϭ 36.62; p Ͻ .0001). As The TH mRNA response to restraint stress following chronic vehicle or valproate treatment (baseline vehicle control: n ϭ 11, post-stress vehicle-treated: n ϭ 9, baseline valproate: n ϭ 9, post-stress valproate: n ϭ 10). Mean integrated density is expressed as a percent of non-stressed, vehicle-treated control. *: post-stress value significantly different from respective unstressed baseline (p Ͻ .05). ϩ: valproate-treated baseline significantly different from vehicletreated control baseline (p Ͻ .05).
in the acutely treated animals, post-hoc analyses revealed that the magnitude of the increase in plasma ACTH was significantly less in the chronic valproatetreated rats compared to their vehicle-treated counterparts (p Ͻ .05, Figure 5B ).
DISCUSSION
In this study, the effects of acute and chronic treatment with the antimanic drug valproate on gene expression for components of the central noradrenergic system were determined. Both acute and chronic treatment with valproate induced increases in TH mRNA expression in the locus coeruleus, though the increase in the acutely treated animals was less robust than that in the chronically-treated animals. Moreover, the acute increase was less consistent, as it was not detected in the second experiment, suggesting that the modest increases seen after acute treatment may have represented the very earliest stages of drug-induced changes in TH mRNA expression in LC after valproate treatment. By contrast, the approximate 25% increase in TH mRNA expression seen in the LC of chronic VPAtreated animals was more robust and more consistent, suggesting that the VPA effects had stabilized by this later time point. Moreover, this effect appeared to be specific to TH, in that neither acute nor chronic VPA produced any changes in NET or ␣ 2A receptor mRNA expression in the same LC noradrenergic neurons. The observed increase in TH mRNA expression in the LC is consistent with a previous report of increased TH protein in the brain following chronic VPA treatment . As the LC is the source of hippocampal NE, and TH is the rate-limiting enzyme in NE biosynthesis, our results are also consistent with a previous report that chronic administration of VPA increased hippocampal NE levels by 29% (Baf et al. 1994) .
It is possible that VPA exerts a direct pharmacological effect on gene expression in the NE system via stimulation of cellular effector processes and subsequent activation of transcription factors. Two weeks of treatment with VPA increased the DNA binding activity of AP-1, but not CREB, in C6 glioma cells ., and VPA also stimulated transcriptional activity mediated by AP-1 (Chen et al. 1999) . The promoter regions of the rat TH gene (Cambi et al. 1989) , the mouse NET gene (Fritz et al. 1998 ) and the rat ␣ 2A gene (Yang et al. 1997 ) all contain AP-1 sites, though only the AP-1 site in the TH gene has been reported to functionally activate gene transcription (Icard-Liepkalns et al. 1992 ). Thus, it is possible that the AP-1 site may be involved in the elevation of TH mRNA expression seen with valproate treatment, but the specificity of the response may require the involvement of other factors that do not regulate the NET or ␣ 2A genes to the same extent. For instance, chronic VPA treatment has been shown to decrease levels of PKC alpha and epsilon (Chen et al. 1994 ). This has been suggested to be a result of chronic PKC activation (Manji and Lenox 1994) , and activation of PKC by administration of phorbol ester activates TH gene transcription (Vyas et al. 1990 ). Chronic VPA treatment has also been shown to decrease levels of myristoylated alanine-rich C kinase substrate (MARCKS) (Lenox et al. 1996) , providing further evidence of an interaction of VPA with PKC. Similar effects on PKC activity and MARCKS have been observed following administration of lithium, another effective antimanic agent (Manji et al. 1996; Manji and Lenox 1994) .
Valproate-induced increases in TH mRNA expression in the locus coeruleus may also be attributable in part to an indirect effect exerted via changes in GABAergic neurotransmission in the brain. The antiepileptic effects of VPA are thought to be mediated through inhibition of GABA transaminase, increasing GABA extracellularly and thus suppressing seizure activity (Loscher 1993) . VPA has also been demonstrated to potentiate the hyperpolarizing effects of GABA on neuronal activity of the LC (Olpe et al. 1988) . By enhancing the effects of GABA, VPA may therefore inhibit LC neuronal activity and decrease NE release (Os- manovic and Shefner 1990). However, TH expression has been shown to increase with depolarization of A6 neurons in vitro (Dreyfus et al. 1986) . It has further been demonstrated in vivo that stimuli which elevate TH mRNA expression in the LC tend to elevate the activity of LC neurons (Melia et al. 1992 ). Thus, it seems unlikely that the elevation in TH gene expression induced by VPA was a direct result of enhanced GABAergic inhibition of LC neuronal activity. Rather, it would seem more likely to be the result of indirect compensatory or reactive homeostatic processes mediated by long-loop feedback circuits conveying information about changes in effective NE neurotransmission in post-synaptic target regions of the LC.
In addition to an elevation in basal TH message expression, chronic treatment of rats with VPA attenuated the increase in TH message expression seen in response to acute restraint stress, perhaps reflective of a VPAinduced decrease in stress-reactivity of the noradrenergic system. Because chronic VPA treatment itself induced an increase in basal expression of TH mRNA, it is possible that any subsequent stress-induced increase could have been more difficult to detect. However, it is unlikely that the lack of a stress-induced increase in TH mRNA expression was due to a ceiling effect, because the magnitude of the increase in basal expression produced by chronic VPA does not appear to be near maximal. Reserpine administration has been reported to induce up to several-fold increases in TH mRNA expression (McMahon et al. 1992) . When reserpine (10 mg/kg, i.p.) was administered to a small number of animals that were processed together with the subjects in the current study, we observed a 55% increase in TH mRNA in the LC measured 48 hours after reserpine treatment (unpublished observation). As compared to the 25% increase in basal expression induced by chronic VPA, this would suggest that there was still some capacity for stress to increase TH mRNA expression in the LC after chronic VPA treatment. Thus it appears that chronic VPA attenuated the acute stress-reactivity of the LC, at least the component of reactivity represented by stress-induced changes in TH gene expression.
In addition to attenuating the increase in TH mRNA following stress, valproate also attenuated acute restraint stress-induced increases in plasma ACTH levels, with no apparent effect on pre-stress basal ACTH. Similar effects of VPA on ACTH or corticosterone levels have been reported in rats using ether stress (Jones et al. 1984) or restraint stress (Petraglia et al. 1986 ). Further, VPA reduced the elevated plasma ACTH levels seen in humans with Nelson's or Cushing's disease without altering ACTH levels in normal human volunteers (Elias et al. 1981; Jones et al. 1984) . However, basal hypothalamic CRF and plasma corticosterone, but not ACTH, have been reported to be elevated in valproate-treated rats (Jones et al. 1984) . These investigators further showed that the response to CRF in the anterior pituitary was reduced, indicating an alteration in CRF receptor expression and/or activity. These findings suggest that valproate can perhaps selectively counteract dysregulation of the HPA axis, often associated with affective disorders, without affecting basal activity.
Central NE is hypothesized to facilitate stressinduced HPA activation through stimulation of ␣ 1 adrenergic receptors (Gibson et al. 1986; Kiss and Aguilera 1992; Plotsky 1987; Szafarczyk et al. 1987) . Therefore, a reduction in central noradrenergic reactivity induced by VPA may contribute to the attenuation of acute stress-induced HPA activation seen following VPA treatment. Whereas it is unlikely, for the reasons discussed above, that VPA influenced TH mRNA expression in the LC by modulating GABA neurotransmission, it is possible that this mechanism does play a role in attenuating stress-induced ACTH secretion.
Current hypotheses suggest that dysregulation of NE neurotransmission may occur in qualitatively opposite directions in certain forms of depressive illness as compared to bipolar disorder or mania (Schatzberg and Schildkraut 1995) . Consistent with this, the effects exerted by antidepressant drugs on TH gene expression in the LC appear to be opposite in nature to the effects of VPA observed in the present study. In contrast to the increase observed following VPA treatment, we and others have shown a decrease in TH mRNA expression following chronic antidepressant treatment (Brady et al. 1991; Morilak et al. 1998; Nestler et al. 1990 ). There is also evidence for opposing effects of antidepressants and VPA on second messengers in the NE neurotransmitter system. In contrast to the increase in PKC activity elicited by VPA, chronic treatment with desipramine caused a decrease in PKC activity in the particulate fractions of the cortex and hippocampus (Mann et al. 1995) . These observations are consistent with theories suggesting that monopolar depression and bipolar affective disorder may involve underlying mechanisms that are qualitatively opposite in nature.
The dysregulation of the HPA axis that is often associated with a variety of affective disorders may also reflect abnormalities in specific modulatory neurotransmitter systems, such as the noradrenergic system, that are involved in both the regulation of mood and in the response to stress. Drugs that are effective in treating such disorders, including novel antimanics such as valproate, may induce regulatory changes in these systems that result in the stabilization and normalization of both mood and stress reactivity. Lithium, another antimanic drug, has also been shown to attenuate stress-mediated effects in rats, although the neuroendocrinological effects of lithium with regard to the HPA axis have not been well-examined (Kofman et al. 1995) . The results of the present study and others (Jones et al. 1984; Delbende et al. 1991) would suggest that both antimanics and anti-depressants can attenuate stress-induced increases in HPA activity. Thus, whereas each type of drug can induce different, even opposite regulatory changes in the neurotransmitter systems that modulate mood and stress reactivity, an indirect result in each case may be the stabilization of systems such as the HPA axis that may be dysregulated secondarily, and in a similar fashion, in these very different mood disorders.
